CMC Biologics Adds 2,000 Liter Single-Use Bioreactor at its Copenhagen Manufacturing Facility

Several planned events highlight CMC Biologics' expertise in single-use technology

COPENHAGEN, Denmark and SEATTLE, Sept. 1, 2011 /PRNewswire/ -- CMC Biologics today announced the completion of the installation of a 2,000 liter single-use bioreactor (2,000L SUB) at its manufacturing facility in Copenhagen. The Thermo Scientific HyClone SUB, one of several SUBs CMC Biologics has in its manufacturing facilities in Copenhagen and Seattle, will begin shake-down runs and is expected to be ready for GMP contract manufacturing by December 2011.

(Logo:  http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

According to Gustavo F. Mahler, Ph.D., Global Chief Operations Officer of CMC Biologics, "The expansion of the facility to include the 2,000L SUB will allow us to meet increasing demand for producing biologicals for Phase III and into market supply. The advantages for CMC Biologics and our customers are clear: reduced project times, reduced risk of cross-contamination resulting in increased process reliability and reduced batch manufacturing costs that will allow CMC Biologics to be even more competitive." Mahler added, "We have worked closely with Thermo Fisher Scientific to bring this project in on time and on budget."

"It has been our pleasure to work with CMC Biologics. With their leadership in contract biopharmaceutical manufacturing and applying single-use systems, it is not surprising that our first 2,000L SUB in Europe is being installed at their Danish facility," stated Brandon Pence, Global Director of Marketing, Cell Culture and Bioproduction, Thermo Fisher Scientific.

Forthcoming Single-Use Technology Events

Webinar: Practical and Theoretical Implications of Single Use Bioreactor Technology

Date: Thursday, September 15, 2011

Start Time: 14:15 GMT+1

Duration: 1 hour

For more information: www.wtgwebinar.com/thermofisher_agenda

ISPE Nordic Conference: Single Use Technology in Pharmaceutical Production

Date: October 5, 2011

Location: Uppsala, Sweden

For more information: www.ispe.org/nordic

Single-Use Technology Seminar

Co-sponsored by Applikon Biotechnology, BioProcess International, CMC Biologics, and Thermo Fisher Scientific

Date: Tuesday and Wednesday, October 25-26, 2011

Location: Clarion Hotel in Copenhagen, Denmark

This event will provide an opportunity to view the 2,000L SUB at CMC Biologics' facility in Copenhagen during a facility tour and reception on Tuesday evening.

For more information: http://events.SignUp4.com/copenhagen2011

About CMC Biologics

CMC Biologics (www.cmcbio.com) is a dedicated contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes. For more information, please visit www.cmcbio.com.

SOURCE CMC Biologics

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.